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Abstract: Atherosclerosis is a chronic inflammatory disease promoted by hyperlipidemia. Several studies
support FOXP3-positive regulatory T cells (Tregs) as inhibitors of atherosclerosis; however, the mech-
anism underlying this protection remains elusive. To define the role of FOXP3-expressing Tregs in
atherosclerosis, we used the DEREG mouse, which expresses the diphtheria toxin (DT) receptor under
control of the Treg-specific Foxp3 promoter, allowing for specific ablation of FOXP3+ Tregs. Lethally ir-
radiated, atherosclerosis-prone, low-density lipoprotein receptor-deficient (Ldlr-/-) mice received DEREG
bone marrow and were injected with DT to eliminate FOXP3+ Tregs. Depletion of Tregs caused a 2.1-
fold increase in atherosclerosis without a concomitant increase in vascular inflammation. These mice also
exhibited a 1.7-fold increase in plasma cholesterol and an atherogenic lipoprotein profile with increased
levels of VLDL. Clearance of VLDL and chylomicron remnants was hampered, leading to accumulation
of cholesterol-rich particles in the circulation. Functional and protein analyses complemented by gene
expression array identified reduced protein expression of sortilin-1 in liver and increased plasma enzyme
activity of lipoprotein lipase, hepatic lipase, and phospholipid transfer protein as mediators of the altered
lipid phenotype. These results demonstrate that FOXP3+ Tregs inhibit atherosclerosis by modulating
lipoprotein metabolism.
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Atherosclerosis is a chronic inflammatory disease promoted by hyperlipidemia. Several studies support FOXP3- 
positive regulatory T cells (Tregs) as inhibitors of atherosclerosis; however, the mechanism underlying this 
protection remains elusive. To define the role of FOXP3-expressing Tregs in atherosclerosis, we used the 
DEREG mouse, which expresses the diphtheria toxin (DT) receptor under control of the Treg-specific Foxp3 
promoter, allowing for specific ablation of FOXP3+ Tregs. Lethally irradiated, atherosclerosis-prone, low-den-
sity lipoprotein receptor–deficient (Ldlr–/–) mice received DEREG bone marrow and were injected with DT to 
eliminate FOXP3+ Tregs. Depletion of Tregs caused a 2.1-fold increase in atherosclerosis without a concomi-
tant increase in vascular inflammation. These mice also exhibited a 1.7-fold increase in plasma cholesterol and 
an atherogenic lipoprotein profile with increased levels of VLDL. Clearance of VLDL and chylomicron rem-
nants was hampered, leading to accumulation of cholesterol-rich particles in the circulation. Functional and 
protein analyses complemented by gene expression array identified reduced protein expression of sortilin-1 
in liver and increased plasma enzyme activity of lipoprotein lipase, hepatic lipase, and phospholipid transfer 
protein as mediators of the altered lipid phenotype. These results demonstrate that FOXP3+ Tregs inhibit 
atherosclerosis by modulating lipoprotein metabolism.
Introduction
Cardiovascular disease remains a major cause of death and mor-
bidity despite currently available drug therapies (1). Atherosclero-
sis constitutes the underlying cause of the clinical manifestations 
of myocardial infarction, stroke, and gangrene, and is recognized 
as a chronic inflammatory disease involving a variety of immuno-
logical features (2). Subendothelial lipid retention and oxidative 
modification in the arterial wall elicit a chronic inflammatory pro-
cess characterized by the formation of an immune cell infiltrate 
dominated by lipid-laden macrophage foam cells and T cells (2–4). 
The accumulation and activation of these immunological cells 
play a pivotal role in the development of atherosclerotic lesions.
Both innate and adaptive immunity are involved in the patho-
genesis of atherosclerosis. Pattern recognition receptors of innate 
immunity account for cholesterol uptake and contribute to the 
activation of macrophages and endothelial cells. Antigen-specific 
T cells recognizing LDL in the intima constitute the adaptive 
immunity component in the pathogenesis of atherosclerosis and 
elicit proinflammatory stimuli that further exacerbate and prop-
agate this disease (5). Inherent atheroprotective immune mecha-
nisms include natural antibodies to LDL-derived phospholipids 
and antiinflammatory immune cells such as regulatory T cells 
(Tregs). Strategies to mobilize and stimulate immunosuppression 
may provide novel therapeutic approaches to reduce atheroscle-
rotic cardiovascular disease (6, 7).
Tregs were initially characterized as CD4+CD25+ T cells that 
could suppress the activity of effector T cells (8). Further studies 
have identified several varieties of Tregs (9). The forkhead box tran-
scription factor, FOXP3, was identified as the key lineage marker 
and master switch in the regulation of Treg development and func-
tion (10–12). FOXP3 is now accepted as the “gold standard” for 
defining thymic-derived Tregs (9). Accordingly, selective depletion 
of FOXP3+ Tregs reproduces the hyperinflamed, scurfy pheno-
type observed in Treg-deficient mice (13). In contrast, depletion 
of CD4+CD25+ T cells by administration of an antibody targeting 
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the interleukin-2 (IL-2) receptor α-chain (CD25) on the surface of 
T cells failed to reproduce the fulminant disease phenotype of 
scurfy mice (14, 15). This indicates that the CD4+CD25+ T cell pop-
ulation only partly overlaps with the FOXP3+ Treg cell population.
Transfer experiments in immune-deficient, hyperlipidemic 
mice show that CD4+CD25+ cells with features of natural Tregs 
are atheroprotective (16). Accordingly, IL-10 and TGF-β, the 2 
major cytokine products of Tregs, are powerful inhibitors of the 
atherosclerotic process in similar mouse models (17–20). Several 
questions remain, however, with respect to the mechanism of 
how Tregs impact atherosclerosis progression (21). To address 
these questions, we have adapted a model that permits condi-
tional depletion of Tregs in a mouse model of atherosclerosis. The 
recently described DEREG (depletion of regulatory T cells) mouse 
(13) expresses a fusion protein of the human diphtheria toxin (DT) 
receptor (hDTR) and enhanced green fluorescent protein (eGFP) 
under control of the Foxp3 promoter introduced by BAC technol-
ogy. The expression of eGFP under control of the Foxp3 promoter 
permits tracking of transgenic eGFP+ Tregs. FOXP3+ Tregs can 
be selectively depleted upon DT administration in DEREG mice, 
since wild-type mice do not express the hDTR receptor and are 
thus insensitive to DT.
We transplanted bone marrow from DEREG mice into lethally 
irradiated, atherosclerosis-prone, LDL receptor-deficient (Ldlr–/–) 
mice, identified eGFP+ Tregs in atherosclerotic lesions, admin-
istered DT to ablate FOXP3+ Tregs, and analyzed the effects on 
immunity, metabolism, and atherosclerosis. Depletion of Tregs 
led to a dramatic increase in atherosclerotic lesions, but did not 
increase vascular inflammation. However, it associated with 
impaired clearance of large lipoproteins, leading to a 70% increase 
in plasma cholesterol, with a robust increase in VLDL levels. These 
data identify a previously unknown function of Tregs as modula-
tors of lipid metabolism.
Results
Long-term DT treatment is tolerated in DEREG mice. We achieved 
effective depletion of 99% of transgenic eGFP+ Tregs in peripheral 
blood for more than 3 days after i.p. administration of a single 
dose (0.125 μg/mouse) of DT to DEREG mice (Supplemental 
Figure 1A; supplemental material available online with this arti-
cle; doi:10.1172/JCI63891DS1). Based on these findings, a twice-
weekly DT administration regimen was chosen for all subsequent 
experiments. To evaluate the long-term safety in DEREG mice, 
DT was administered i.p. twice weekly for 8 weeks to DEREG and 
wild-type mice at 0.125 or 0.25 μg/mouse (20 g body weight). The 
higher DT dose was found to be associated with signs of toxic-
ity (fatigue, changes in fur appearance, loss of appetite), while no 
obvious adverse effects were observed at the lower dose in DEREG 
or wild-type mice. Accordingly, the low DT dose was chosen for 
long-term administration in the atherosclerosis study.
DT administration eliminates functional Tregs in chimeric DEREG/
Ldlr–/– mice. DEREG bone marrow was transplanted into lethally 
irradiated Ldlr–/– mice that received an atherogenic diet to promote 
hypercholesterolemia and atherosclerosis. One group of the chi-
meric DEREG/Ldlr–/– mice received DT twice weekly for 8 weeks to 
eliminate FOXP3+ Tregs. The FOXP3-driven coordinate expression 
of eGFP and hDTR permitted an identification of FOXP3+ cells in 
bone marrow chimeras not receiving DT and an evaluation of the 
efficiency of Treg depletion in the DT-treated mice.
Effective depletion of transgenic (eGFP+) Tregs in inguinal 
lymph nodes (Figure 1A) and lymphoid organs (not shown) was 
achieved by DT administration to chimeric DEREG/Ldlr–/– mice. 
The suppressor function of total Tregs was markedly impaired, 
as documented by robustly increased proliferation of lymph node 
cells from mice treated with DT versus PBS (Figure 1B).
In a separate experiment, chimeric DEREG/Ldlr–/– mice were 
treated with DT versus PBS and bled at different intervals after 
initiation of treatment. Flow cytometric data on the kinetics of 
Tregs revealed that over time, depletion of eGFP+ Tregs became less 
effective. Ten days after initiating DT administration, complete 
depletion of transgenic Tregs was achieved, followed by a gradual 
recovery of these GFP+FOXP3+ cells. The total number of FOXP3+ 
cells was not substantially reduced due to a compensatory increase 
in GFP–FOXP3+ cells (Supplemental Figure 1, B–D). Plasma lev-
els of the inflammatory marker, serum amyloid A (SAA), did not 
differ between groups (Table 1). DT treatment thus led to persis-
tently perturbed immunoregulation with increased T cell activ-
ity, though without signs of overt systemic inflammation after 
8 weeks of treatment.
To define the source of eGFP– (nontransgenic) FOXP3+ Tregs, 
we transplanted DEREG bone marrow (on a C57Bl/6 background, 
thus expressing the CD45.2 isoform) into Ldlr–/– mice carrying the 
CD45.1 surface marker. FACS analysis of spleen cells showed that 
eGFP– (nontransgenic) FOXP3+ Tregs were predominantly derived 
from the CD45.1+ recipient Ldlr–/– mice (Supplemental Figure 2, 
A and B). Furthermore, nontransgenic CD45.1+ eGFP– cells pre-
Figure 1
Effective depletion of transgenic Treg cells is achieved in chimeric 
DEREG/Ldlr–/– mice. (A) Proportions of cells expressing eGFP within 
the CD3+CD4+ population in inguinal lymph nodes from chimeric 
DEREG/Ldlr–/– mice treated with DT or PBS harvested at 4 and 8 
weeks, respectively (n = 6–7 mice per group). (B) Proliferation of lymph 
node cells from chimeric DEREG/Ldlr–/– mice treated for 8 weeks with 
DT or PBS and stimulated in vitro with anti-CD3. Data show stimulation 
index based on 3H-thymidine uptake (n = 4 mice per group). *P < 0.05.
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dominated among FOXP3+ cells in the DT-treated mice, whereas 
CD45.2+ eGFP+ cells constituted the majority of FOXP3+ cells in 
PBS controls. This suggests a replenishment of the total FOXP3+ 
Treg pool from this niche that could only partially compensate for 
the loss of functional FOXP3+ Tregs upon DT treatment (Supple-
mental Figure 1, B–D). This interpretation is in line with the recent 
finding of functionally defective cell subsets carrying certain Treg 
markers in DEREG mice (22).
Treg depletion aggravates atherosclerosis in chimeric DEREG/Ldlr–/– 
mice. DT treatment of chimeric DEREG/Ldlr–/– mice caused a pro-
nounced 2.1-fold increase in the size of atherosclerotic lesions 
in the aortic sinus (3.23 × 105 ± 0.39 × 105 μm2 vs. 1.54 × 105 ± 
0.21 × 105 μm2; P = 0.0026) and a 1.9-fold increase in relative lesion 
area (lesion cross-sectional area/total vessel area; 30.0 ± 3.1% 
vs. 16.0 ± 2.0%; P = 0.003) compared with PBS-treated controls 
(Figure 2). DT treatment did not affect lesion size in Ldlr–/– mice 
reconstituted with wild-type bone marrow (Figure 2C), indicating 
that the augmented lesion development upon DT treatment of 
DEREG/Ldlr–/– mice was due to the loss of Treg activity.
DT-mediated Treg depletion led not only to increased atheroscle-
rotic lesion size, but was also associated with reduced immune cell 
infiltration into atherosclerotic lesions. Immunohistochemical 
analysis identified eGFP+ Treg–expressing FOXP3 in atheroscle-
rotic lesions of PBS-treated DEREG/Ldlr–/– mice (Figure 3A). DT 
treatment resulted in complete disappearance of eGFP+ cells, while 
residual FOXP3+ cells and total CD3+ T cells remained unaltered 
in the lesions and vessel wall (Figure 3, A and B, and Supplemental 
Figure 3). There was a significant reduction in CD68+-stained area 
(macrophages) per lesion surface area (Figure 3C) and similarly 
reduced areas staining positive for cells expressing the murine 
MHC class II molecule, IAb, respectively (Figure 3B). A decrease in 
total cellularity of lesions with fewer macrophages in DT-treated 
mice when calculated as the total number of CD68+ cells per lesion 
surface area was paralleled by an increase in the necrotic core size 
(Figure 3, D and E, and data not shown).
Treg depletion aggravates hypercholesterolemia and monocytosis in chime-
ric DEREG/Ldlr–/– mice. Effects on plasma lipids were dramatic, with 
a 70% increase in plasma cholesterol concentration paralleled by a 
significant decrease in plasma triglycerides (Table 1 and Figure 4A). 
The increase in cholesterol was detectable already during the first 
month of treatment, suggesting that it was causally related to the 
increase in lesion size observed after 8 weeks (Figure 4A).
Gel filtration analysis revealed a pronounced elevation of cho-
lesterol in the VLDL/chylomicron remnant (CMR) fraction in 
DT-treated chimeric DEREG/Ldlr–/– mice (Figure 4B), whereas 
triglyceride content was lower in the VLDL/CMR particles (Fig-
ure 4C). Plasma VLDL/CMR cholesterol levels strongly correlated 
with lesion size (r = 0.956; P = 0.0006), as did total cholesterol and 
LDL cholesterol (Figure 4D and Supplemental Figure 4, A and B). 
Upon DT treatment, plasma apoB concentration was numerically 
increased, suggesting an increased number of VLDL particles 
rather than a larger amount of cholesterol per particle (Table 1). 
DT treatment affected neither body weight nor plasma markers, 
nor liver or kidney function (data not shown). DT-mediated elim-
ination of Tregs from DEREG/Ldlr–/– mice was associated with 
markedly increased monocyte counts in peripheral blood (Table 1). 
No difference was detected in the distribution of monocyte sub-
populations (Table 1). Interestingly, total monocyte counts in 
peripheral blood showed a positive correlation with lesion size 
(Supplemental Figure 4C), and an inverse correlation was found 
with GFP+ Tregs (Supplemental Figure 4D).
Plasma lipids were analyzed in 4 treatment groups of chimeric 
mice: recipient Ldlr–/– mice receiving wild-type bone marrow and 
treated with (a) PBS or (b) DT; or Ldlr–/– mice receiving DEREG bone 
marrow and treated with (c) PBS or (d) DT. Of note, DT treatment 
had no significant effect on atherosclerotic lesions (Figure 2C), total 
cholesterol, triglycerides, body weight, or hematological parameters 
(Table 1). This corroborates previous work showing that lipid levels 
in Apoe–/– mice are not affected by DT administration (23).
Treg depletion impairs lipoprotein catabolism. To determine the 
effects of Treg depletion on VLDL biosynthesis in the liver, we 
analyzed plasma lipids after administering Triton WR-1339, 
which inhibits lipoprotein lipase–dependent (LPL-dependent) 
lipoprotein catabolism. Cholesterol levels in plasma rose to a sim-
ilar extent in both groups (Figure 5A), suggesting that the elevated 
VLDL levels were not due to increased biosynthesis in the liver.
VLDL catabolism was assessed after i.v. injections of FITC- 
labeled mouse VLDLs. This analysis revealed significantly impaired 
Table 1
Body weight, lipid profile, and hematological parameters in bone marrow chimeras: effect of Treg depletion (DT) versus control (PBS)
 Wild-type bone marrow into Ldlr–/– DEREG bone marrow into Ldlr–/– P value
Treatment PBS DT PBS DT All groups Pairwise
Group alias A B C D 
Body weight (g) 25.3 ± 0.9 25.1 ± 0.9 25.7 ± 0.6 24.2 ± 0.8 NS 
Total cholesterol (mM) 20.8 ± 1.6 22.8 ± 1.7 15.3 ± 1.5 26.0 ± 1.5 * #, §
Triglycerides (nM) 4.2 ± 0.5 3.4 ± 0.7 3.5 ± 0.3 2.2 ± 0.6 * ‡, §
ApoB (μg/dl) n.d. n.d. 328.1 ± 30.7 420.3 ± 29.9 NS
Serum amyloid A (pg/ml) n.d. n.d. 200 ± 71 223 ± 99 NS
Leukocytes (103/μl) 13.9 ± 1.3 16.2 ± 1.3 12.3 ± 0.7 14.9 ± 1.2 NS
Monocytes (103/μl) 1.5 ± 0.3 1.2 ± 0.4 0.8 ± 0.2 2.1 ± 0.3 * #, §
Ly6Chi/monocytes (%) n.d. n.d. 47.2 ± 4.5 42.1 ± 3.3 NS
Lymphocytes (103/μl) 10.7 ± 1.0 12.8 ± 1.2 9.1 ± 0.9 11.2 ± 1.3 NS
Erythrocytes (106/μl) 9.3 ± 0.3 9.4 ± 0.3 9.2 ± 0.3 9.6 ± 0.3 NS
Platelets (103/μl) 1,012 ± 88 1,003 ± 91 1,156 ± 95 960 ± 83 NS
Mean ± SEM. All groups (Kruskal-Wallis test) followed by pairwise comparisons (Mann-Whitney U test) if P < 0.05 indicated by *; #A vs. C; ‡B vs. D; §C vs. D; 
n.d., not determined.
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clearance of VLDL particles in Treg-depleted DEREG/Ldlr–/– mice 
(Figure 5B). The gel filtration approach cannot resolve VLDLs 
from CMR particles, and we therefore analyzed chylomicron 
(CM) catabolism by using a double-isotope technique that per-
mitted evaluation of triglyceride and particle elimination. Rats 
received [14C]-oleate and [3H]-retinol by intragastric infusion; 
CMs containing [14C]-triglyceride and [3H]-retinol were isolated 
and injected into DEREG/Ldlr–/– mice treated with PBS or DT. 
Analysis at different time points after injection showed delayed 
clearance of retinol without concomitant changes in triglycerides, 
reflecting a putative defect in core particle turnover (Figure 5C 
and Supplemental Figure 5). Liver uptake of [3H]-retinol was sig-
nificantly reduced, indicating hampered uptake of CM particles 
in DT-treated animals (Figure 5D). Together, our studies of lipo-
protein metabolism show that the elevated plasma cholesterol in 
DT-treated DEREG/Ldlr–/– mice was a result of reduced clearance 
of VLDL and CM remnants.
Treg depletion modulates expression of liver genes involved in lipopro-
tein metabolism. To assess the effect of Treg depletion on genes 
controlling metabolism, a global gene expression array was per-
formed on mRNA isolated from the 2 major organs involved in 
lipoprotein metabolism — liver and intestine — comparing DT- 
versus PBS-treated chimeric DEREG/Ldlr–/– mice. It revealed that 
Treg elimination caused substantial changes in the expression 
pattern of genes regulating metabolism as well as inflammation 
and immunity in liver (Figure 6), whereas no significant changes 
were detected in intestine (data not shown). In the 2 latter groups 
of genes (clusters 2, 3, 5, 6, and 7), expression was increased for 
virtually all genes in DT-treated animals, whereas a more complex 
pattern was observed for metabolic genes (clusters 1 and 4).
Quantitative PCR analysis of specific mRNA species showed 
increased expression of the 2 proinflammatory cytokines IFN-γ 
and TNF-α and of the T cell marker CD3, implying increased Th1-
type inflammatory activity in the liver of DT-treated chimeric 
mice (Figure 7). In contrast, no effects were registered for genes 
involved in NKT cell control of lipase activity (Supplemental Fig-
ure 6), although this pathway was previously reported to modulate 
lipoprotein metabolism (24).
No changes were observed in the mRNA levels of a set of genes 
involved in lipoprotein biosynthesis, including Apo3, Apob, and 
diacylglycerol acyltransferase (Dgat) (Figure 7). In contrast, sev-
eral genes involved in lipoprotein catabolism showed differential 
expression upon Treg depletion (Figure 7). Lpl and hepatic lipase 
(Lipc) were both upregulated, as was the VLDL receptor. mRNA 
for phospholipid transfer protein (Pltp) was also significantly 
increased. In contrast, mRNA for the VLDL binding protein, sor-
tilin-1, was significantly reduced and activating transcription fac-
tor-3 (Atf3), a transcription factor that represses sortilin-1 expres-
sion, was robustly enhanced in the livers of Treg-depleted mice 
(Figure 7). Western blot analysis confirmed that sortilin-1 protein 
was significantly reduced under these conditions, indicating that 
sortilin-1 is a target of Treg depletion (Figure 8, A and B).
Treg depletion increases activity of LPL, hepatic lipase, and PLTP in 
plasma. To further evaluate factors involved in VLDL/CMR metab-
olism, we analyzed LPL and hepatic lipase (HL) activity in posthep-
arin plasma (Figure 8, C and D). The lipolytic activities of these 
2 enzymes were significantly increased in DT-treated chimeric 
DEREG/Ldlr–/– mice. Plasma PLTP activity was also significantly 
increased in Treg-depleted bone marrow chimeras (Figure 8E). In 
contrast, lecithin:cholesterol acyl transferase (LCAT) activity was 
not affected (data not shown). Together, these alterations may 
explain the difference in clearance between triglycerides and core 
particle labels resulting in triglyceride-poor VLDL particles in the 
circulation of Treg-depleted mice.
Discussion
Regulatory immunity has been implicated in atherosclerosis, but the 
mechanism and target organ(s) of atheroprotection remain largely 
Figure 2
Depletion of transgenic Tregs aggravates atherosclerosis. (A) Rep-
resentative photomicrographs showing Oil Red O- and H&E-stained 
sections from the proximal aorta of chimeric DEREG/Ldlr–/– mice 
treated for 8 weeks with PBS or DT. (B) Quantification of lesion size in 
cross-sections of the proximal aorta at different levels from the valves; 
n = 11–12 (PBS) mice and n = 5–8 (DT) mice, respectively. (C) Relative 
lesion area (lesion area/area inside external elastic lamina × 100) cal-
culated from 4 sections per mouse (300–600 μm) for wild-type/Ldlr–/– 
and DEREG/Ldlr–/– mice treated for 8 weeks with PBS or DT, respec-
tively. *P < 0.05; **P < 0.01. Scale bars: 100 μm.
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unknown. We now show in the chimeric DEREG/Ldlr–/– model that: 
(a) depletion of FOXP3+ Treg leads to substantially increased ath-
erosclerosis; (b) elimination of FOXP3+ Tregs aggravates hypercho-
lesterolemia; and (c) VLDLs and CMRs are dramatically elevated in 
plasma due to reduced clearance in the absence of the LDL recep-
tor. Together, these findings establish that FOXP3+ Tregs exert an 
important atheroprotective effect, and show that plasma lipopro-
tein metabolism is modulated in part by regulatory immunity.
Previous studies demonstrated that regulatory immunity 
affects atherosclerosis progression. Elimination of CD4+CD25+ 
cells increases disease severity, and the transfer of T cells from 
Cd28–/– mice is associated with reduced numbers of CD4+CD25+ 
natural Tregs accelerating atherosclerosis in Ldlr–/– mice (16). Sim-
ilarly, Ldlr–/– mice deficient in ICOS displayed decreased FOXP3+ 
T cells and increased atherosclerosis (25), while expansion of 
the circulating Treg pool in Apoe–/– mice by CD31 administra-
tion reduced atherosclerosis (26), as did the adoptive transfer 
of CD4+CD25+ cells from atherosclerotic to disease-prone mice 
(27). Furthermore, expansion of another regulatory T cell pool, 
the Tr1 cell population, by global or antigen-specific methods, 
also reduces atherosclerosis in Apoe–/– mice (28, 29). While all 
these studies highlight the role of regulatory cellular immunity 
in atherosclerosis, direct evidence for atheroprotective actions of 
FOXP3-driven immunity is lacking.
We now provide such evidence by using the DEREG model. We 
had expected that elimination of Tregs would unleash plaque 
inflammation, causing enhanced production of several proinflam-
matory mediators. Instead, immune cells and local inflammatory 
markers in the lesions were either unchanged or reduced when 
Tregs were depleted, which is likely attributable to the advanced 
stage of lesions with low cellularity in DT-treated mice. Circulating 
levels of the inflammatory marker SAA remained unaltered, and 
while monocyte counts were elevated, no changes were registered 
between monocyte subclasses. Together, these data suggest that 
modulation of vascular inflammation may not be the only, and per-
haps not even the major, target of Treg control in atherosclerosis.
DT treatment of DEREG/Ldlr–/– mice profoundly reduced the 
population of GFP+FOXP3+ Tregs. This led to a more than 3-fold 
Figure 3
Depletion of Tregs affects cellular composition of atheroma. (A) Rep-
resentative fluorescence micrographs depicting eGFP+FOXP3+ cells 
(arrowheads) and eGFP–FOXP3+ (arrows) cells in aortic lesions of 
DEREG/Ldlr–/– mice treated for 8 weeks with PBS or DT. Anti-GFP 
was labeled with AlexaFluor 488 (green), anti-FOXP3 with Alex-
aFluor 555 (red), and nuclei with DAPI (blue). (B) Quantitation of 
immunohistochemical staining for T cells (CD3+), Tregs (FOXP3+), and 
I-Ab–expressing (MHCII-expressing) cells (all expressed as stained 
cells per lesion area) in the proximal aorta of chimeric DEREG/Ldlr–/– 
mice treated for 8 weeks with DT or PBS; n = 7–8 mice per group. 
(C) Quantitation of immunohistochemical staining for macrophages 
(CD68+), dendritic cells (CD11c+), and expression of the adhesion mol-
ecule VCAM-1 (all expressed as stained area per lesion area) in the 
aortic sinus of chimeric DEREG/Ldlr–/– mice treated for 8 weeks with 
DT or PBS; n = 7–8 mice per group. (D) Cellularity of atherosclerotic 
lesions (DAPI+ nuclei per lesion area) in the proximal aorta of chimeric 
DEREG/Ldlr–/– mice treated for 8 weeks with PBS or DT; n = 7–8 mice 
per group. (E) Necrotic core area relative to total atherosclerotic lesion 
area in the proximal aorta of chimeric DEREG/Ldlr–/– mice treated for 
8 weeks with PBS or DT; n = 7–8 mice per group. *P < 0.05; **P < 0.01. 
Scale bars: 50 μm.
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increase in effector T cell proliferation due to loss of suppressor 
activity. However, it did not cause any substantial reduction in the 
total number of FOXP3+ T cells. Bone marrow transplantation 
(BMT) experiments using CD45 isotypic markers clarified that 
this was due to an expansion of FOXP3+ T cells derived from the 
recipient. This, in turn, may reflect that FOXP3+ cells are less sen-
sitive to irradiation used in the BMT protocol than other T cell 
types. In line with previous data (22), the robust effect of DT treat-
ment on T effector cell proliferation shows that the recipient-de-
rived FOXP3+ T cells were not effective as suppressor cells, possibly 
reflecting that they were not fully differentiated Tregs.
In addition to these changes in FOXP3+ cell populations, it was 
apparent that the depletion of transgenic FOXP3+ Tregs (GFP+ 
FOXP3+) waned over time despite continued DT treatment. This 
may reflect genetic alterations in the artificial Foxp3 promoter, an 
increasingly efficient DT metabolism in the recipients, or immune 
reactions to DT. At any rate, our data show that selective depletion 
of Tregs over an extended period is possible by using the DEREG/
DT strategy; this permits studies of chronic pathological processes 
such as atherosclerosis.
The phenotypic screen of DEREG/Ldlr–/– chimeras revealed 
increased hypercholesterolemia upon Treg depletion, with a 1.7-fold 
increase in total plasma cholesterol. This was due to a dramatic 
increase in large, cholesterol-rich, VLDL/CMR–sized particles. 
Since such particles are highly atherogenic in Ldlr–/– mice (30), it 
is likely that their accumulation in blood crucially contributed to 
the accelerated atherosclerosis observed when Tregs were depleted. 
This notion is supported by the strong correlation between VLDL 
cholesterol concentration in plasma and lesion size. This, in turn, 
suggests that Tregs under normal conditions control VLDL choles-
terol levels and that this contributes to their atheroprotective role.
The clearance of injected VLDLs and CMs was reduced in Treg-ab-
lated DEREG/Ldlr–/– mice. In contrast, neither lipoprotein secretion 
nor mRNA expression of enzymes involved in the VLDL biosynthe-
sis pathway was affected by Treg depletion. Therefore, Tregs modu-
late blood lipid levels by regulating lipoprotein catabolism.
VLDLs and CM particles are catabolized in a complex process 
that involves hydrolysis of triglycerides by several lipases includ-
Figure 4
DT-induced depletion of transgenic Tregs promotes hypercholester-
olemia. (A) Changes in plasma cholesterol levels during treatment of 
DEREG/Ldlr–/– bone marrow chimeras with DT or PBS; n = 5 per group. 
*P < 0.05; **P < 0.01. (B) Fast protein liquid chromatographic (FPLC) 
analysis of plasma lipoprotein profiles from DEREG/Ldlr–/– bone mar-
row chimeras treated for 8 weeks with PBS (gray line) or DT (black 
line). The cholesterol concentration in each fraction (y axis) is plot-
ted against retention time (x axis), with the corresponding lipoprotein 
fractions (identified by human plasma standards) indicated at the top. 
Mean (thick line) and SEM (fine lines) are shown; n = 5 per group. (C) 
FPLC analysis of plasma lipoprotein profiles from DEREG/Ldlr–/– bone 
marrow chimeras treated for 8 weeks with PBS (gray line) or DT (black 
line). The triglyceride concentration in each fraction (y axis) is plot-
ted against retention time (x axis), with the corresponding lipoprotein 
fractions (identified by human plasma standards) indicated at the top. 
Mean (thick line) and SEM (fine lines) are shown; n = 5 per group. (D) 
Spearman’s rank correlation analysis for VLDLs and atherosclerotic 
lesion size in the proximal aorta. Each dot represents an individual 
mouse and the curve is plotted with the corresponding correlation coef-
ficient (r value) displayed. DT is represented by black circles; PBS is 
represented by gray circles.
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ing LPL and HL, and uptake of the remaining cholesterol-rich 
particles through several receptors, mainly in the liver. Among 
them, Vldlr mRNA was increased, Lrp1 mRNA was unchanged, 
and Ldlr was eliminated by gene targeting in the present study. 
However, sortilin-1, a receptor involved both in intracellular 
processing and cell surface uptake of VLDLs, was significantly 
reduced, both in mRNA and protein levels. Furthermore, 
mRNA for ATF3, a sortilin-inhibiting transcription factor, was 
increased, supporting the notion that sortilin-1 expression was 
attenuated in Treg-depleted mice.
Sortilin-1 was recently identified as a major regulator of plasma 
cholesterol in a genome-wide association study (31). It acts 
intracellularly to modulate VLDL secretion by binding apoB-con-
taining particles in the Golgi apparatus and targeting them to a 
lysosomal compartment (32). In addition, sortilin-1 operates on 
the hepatic cell surface, where it binds apoB-containing particles 
and guides them to lysosomal degradation (32). Our current data 
showing that the hypercholesterolemic phenotype was associated 
with reduced sortilin-1 expression is in line with these actions of 
sortilin-1 as a lipoprotein-regulating receptor. It is likely that the 
lack of functional LDL receptors in the chimeric mice augmented 
the lipoprotein-clearing action of sortilin-1. The fact that the 
reduction in VLDL secretion did not reach significance may reflect 
limitations in the assay, or it may mean that the effect on particle 
clearance was more important in the present model.
Nascent VLDL particles are modified by the lipolytic enzymes, 
HL and LPL. Both lipases were upregulated, offering an explana-
tion for the accumulation of cholesterol-rich 
and relatively triglyceride-poor particles in 
Treg-depleted mice. Since sortilin-1–dependent 
clearance was reduced, these lipoprotein parti-
cles continued to circulate while triglycerides 
were persistently catabolized by the lipases, 
which showed elevated expression and activity.
Increased PLTP activity may also contribute 
to the observed phenotype. PLTP transfers 
phospholipids between lipoproteins, modu-
lates HDL composition, and can increase VLDL 
levels (33–35). This results in an atherogenic 
lipoprotein profile with elevated VLDL and 
reduced HDL, increased plasma cholesterol, 
and impaired reverse cholesterol transport. 
Accordingly, hypercholesterolemic mice carry-
ing a PLTP transgene develop accelerated ath-
erosclerosis (36, 37), whereas PLTP deficiency 
protects from disease (38).
In summary, we provide evidence that Treg 
depletion results in significantly accelerated 
atherosclerosis and an atherogenic lipoprotein 
profile that is mediated by reduced clearance of 
large lipoprotein particles. Our findings high-
light that immune mechanisms have an impact 
on metabolic events and show that chronic 
inflammation can promote cardiovascular dis-
ease by instigating metabolic disturbances.
Methods
Animals and treatment protocols. DEREG mice on a 
C57BL/6 background were previously generated (13) 
and were maintained and used as hemizygous trans-
genics. Offspring were typed by flow cytometry for the presence of an eGFP+ 
cell population within the CD3+CD4+ population of peripheral blood cells. 
Bone marrow cells, isolated from the femur and tibia of male 8- to 10-week-
old DEREG– or DEREG+ littermates were i.v. injected (7.5 × 106 cells per 
mouse) into lethally irradiated (14 Gy) 6- to 8-week-old Ldlr–/– mice (The 
Jackson Laboratory). After recovery for 6 weeks, Ldlr–/– mice were fed a high-
cholesterol diet (1.25% cholesterol, 0% cholate; Research Diets). Mice were 
randomly assigned to treatment with DT (6.25 μg/kg body weight, i.p. injec-
tion 2 times per week; Merck, no. 322326) or control (100 μl of endotoxin-
free PBS containing 0.1% BSA). Following 8 weeks of treatment, the mice 
were anesthetized by CO2 asphyxiation and their organs were harvested. 
The treatment groups comprised:
Group A: Wild-type bone marrow injected into Ldlr–/– mice treated for 
8 weeks with PBS; i.p. injection.
Group B: Wild-type bone marrow injected into Ldlr–/– mice treated for 
8 weeks with DT; i.p. injection.
Group C: DEREG bone marrow injected into Ldlr–/– mice treated for 
8 weeks with PBS; i.p. injection.
Group D: DEREG bone marrow injected into Ldlr–/– mice treated for 
8 weeks with DT; i.p. injection.
For certain studies regarding the origin of FOXP3+ cells, Ldlr–/– mice 
were crossed with CD451/1 mice (B6.SJL-Ptprca Pepcb/BoyJ, stock-nr: 
002014, The Jackson Laboratory) to generate Ldlr–/–/CD451/1 mice which 
then received bone marrow from DEREG mice on a regular C57BL/6 
background (CD452/2). Staining for CD45.1/CD45.2 was performed as 
with other cell surface markers using antibodies directed against CD45.1 
and CD45.2 (eBioscience).
Figure 5
VLDL/CMR lipoprotein catabolism is impaired in Treg-depleted mice. (A) Biosynthesis of 
apoB-containing plasma lipoproteins. Data show plasma cholesterol levels in chimeric 
DEREG/Ldlr–/– mice treated for 8 weeks with DT or PBS followed by i.v. administration of 
Triton WR-1339 to inhibit lipoprotein lipase–dependent VLDL catabolism; n = 9 (PBS) and 
n = 7 (DT), respectively. (B) Clearance of injected FITC-VLDL in chimeric DEREG/Ldlr–/– 
mice treated for 8 weeks with DT or PBS. FITC-derived fluorescence was analyzed in 
plasma samples at the indicated time points. Data for each individual were normalized 
to the fluorescence of plasma taken 1 minute after injection; n = 4 per group. (C) In vivo 
turnover of CM particles injected into chimeric DEREG/Ldlr–/– mice treated for 8 weeks with 
DT or PBS. Data show kinetics of the CM [14C] retinol core particle clearance from blood 
and are expressed as radiolabeled moieties corrected for weight; n = 5 (PBS); n = 7 (DT). 
(D) CM [14C] retinol uptake in the liver. Data expressed as radiolabeled moieties corrected 
for weight; n = 5 (PBS); n = 7 (DT). *P < 0.05.
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Figure 6
Gene expression array analysis shows changes in liver transcriptomes upon Treg depletion. Shown here are gene expression heat maps of global 
Affymetrix gene expression array analysis of liver RNA from DEREG/Ldlr–/– mice. The rows correspond to genes and the columns to individual 
mice treated with DT or PBS, respectively. Relative gene expression is shown based on normalization for each gene in the DT- and PBS-treated 
groups. Color coding indicates increased gene expression in red, and decreased expression in blue compared with the other group, respectively. 
Sets of genes involved in functional annotation clusters as defined by the DAVID annotation analysis are grouped accordingly. Arbitrary titles that 
summarize the functional role of displayed genes in a cluster are shown in parentheses. Clusters show differentially expressed transcripts based 
on an FDR less than 0.1 and an absolute linear fold change greater than 1.5.
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Tissue preparation and histological analysis. To evaluate atherosclerotic lesion 
size, a total of 8 cryosections (10 μm) extending cranially from the aor-
tic valves at 100-μm intervals were prepared, stained with Oil Red O and 
hematoxylin, and analyzed using Leica Q500MC image analysis software 
(19). Lesion area per cross-section and relative area of lesions were quan-
tified and the results expressed as the mean of 4 consecutive sections per 
mouse available for all individual mice. In brief, relative lesion area was 
calculated for each section as F% = (100 × L/A), where L is lesion area and 
A is area inside the external elastic lamina. F% is averaged over all levels 
analyzed (300–600 μm2 above aortic cusps), and the mean is calculated for 
each treatment group. This method eliminates artifacts caused by oblique 
sections. Necrotic core was expressed as acellular area per lesion area.
Immunolocalization studies. Primary antibodies used for immuno histo-
chemistry comprised anti-CD68 (AbD Serotec), anti–VCAM-1 and anti–
I-Ab (both BD Biosciences), anti-CD3 (Southern Biotechnology), and 
anti-FOXP3 (eBioscience); all of them were rat IgG to mouse antigens. Iso-
type-matched antibodies were used as controls. Antibodies were titrated 
to optimum performance and applied to acetone-fixed cryosections fol-
lowed by detection using an ABC peroxidase kit and DAB substrate (both 
from Vector Laboratories). Immunofluorescence was performed on aortic 
sections as described (13). Quantification of stainings was documented 
as the ratio of thresholded chromogen to fluorogen area or number of 
stained cells per intimal lesion area and nucleated-positive (DAPI) area. 
Quantitative image analysis was performed independently by 2 investi-
gators blinded to the study protocol using either Quantimed (Leica) or 
analySIS (Olympus) software.
Flow cytometry. Flow cytometry was performed on leukocytes isolated 
from blood, spleen, or inguinal lymph nodes. Primary labeled antibodies 
Figure 7
Treg depletion modulates expression of genes controlling inflammation and lipid metabolism in the liver. Quantitative real-time RT-PCR analysis 
of liver mRNA from DEREG/Ldlr–/– mice treated for 8 weeks with DT or PBS. Signals were normalized to Hprt. *P < 0.05; n = 6 per group. (A) Ifng, 
(B) Tnfa, (C) Cd3, (D) Apoc3, (E) Apob, (F) Dgat, (G) Lpl, (H) Lipc, (I) Vldlr, (J) Pltp, (K) Sort1, and (L) Atf3.
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rimetric kits (Randox Laboratories) according to the manufacturer’s proto-
col. ApoB concentrations were measured by a commercial ELISA following 
the manufacturer’s instructions (ALerCHEK).
Analysis of lipoprotein catabolism and biosynthesis. For in vivo clearance, VLDLs 
(d = 1.006 – 1.019 g/ml) were isolated by ultracentrifugation from pooled 
plasma of Apoe–/– mice in the presence of 2 mM benzamidine, 0.5 mM PMSF, 
and 0.1 U/ml aprotinin. After isolation, VLDLs were dialyzed against PBS 
containing 1 mM EDTA and labeled using a modified version of a previ-
ously described method (42). In brief, 2 mg/ml VLDL was dialyzed over-
night against 0.5M NaHCO3 pH 9.5. Next, 50 μg of FITC (Sigma-Aldrich) 
dissolved in DMSO (1 mg/ml) was added for each milligram of protein in 
VLDLs and incubated at room temperature for 2 hours. Conjugates were 
separated from free fluorochrome by gel filtration using a PD10 column (GE 
Healthcare) eluted with PBS. FITC conjugation was evaluated by absorp-
tion spectroscopy at 495 nm against an FITC standard curve. Protein con-
centration was determined by the Bradford assay (Bio-Rad) and adjusted to 
2 mg/ml. Of this preparation, 100 μl was injected into the tail vein and blood 
samples were collected into EDTA-coated tubes 1, 5, 15, 30, and 60 minutes 
after injection. After centrifugation (1,500 g for 5 minutes), plasma samples 
were diluted 1:20 in PBS and fluorescence (excitation 485 nm, emission 535 
nm) was analyzed using a Fluoroskan Ascent FL plate fluorescence reader 
(Thermo Scientific). Data presented are normalized to the fluorescence mea-
sured in samples obtained at 1 minute (= 100 %).
VLDL synthesis was assessed after irreversibly blocking VLDL catabo-
lism (43). Briefly, fasted mice received Triton WR-1339 (500 mg/kg i.v. 
tyloxapol; Sigma-Aldrich) using a 10% (w/v) solution and were bled from 
the tail into EDTA-coated tubes at the indicated time points. Triglycerides 
and cholesterol were measured in plasma as described above.
For in vivo measurements of CM clearance, uncirculated double-labeled 
([3H]-retinol ester and [14C]-triacylglycerol) CMs were isolated from rat 
intestinal lymph through cannulation of the thoracic duct and handled 
were used for extracellular staining against CD3, CD4, and CD45 isoforms 
CD45.1 and CD45.2 (all from BD Biosciences) and CD25 (eBioscience). 
Intracellular staining was performed using the anti–mouse/rat FOXP3 
Staining Set (eBioscience), rabbit anti-GFP (Invitrogen), and anti-FOXP3 
(eBioscience). The staining procedure to detect monocyte subclasses was 
performed essentially as described (39). Briefly, cells were incubated for 
15 minutes at room temperature with FcBlock (anti–CD16/CD32; eBio-
science) and fixable Aqua LIVE/DEAD stain (Invitrogen). Subsequently, 
the cells were washed and incubated for 45 minutes at room temperature 
with the following antibodies: anti-Ly6G, anti-CD49b, anti-CD19, anti-
CD3, anti NK1.1 (all PE-conjugated), anti–CD11b-PECy7, and anti–Ly6C-
FITC (all from eBioscience). All samples were washed, fixed in 1% formalin, 
and analyzed on a CyAn ADP Analyzer using Summit version 4.3 software 
(both Beckman Coulter).
Functional immune assays. Inguinal lymph node cells were isolated by 
meshing lymph nodes from individual mice through a 100 μm nylon mesh 
followed by osmotic lysis of red blood cells (EL buffer; QIAGEN). Cells 
were washed in PBS, cultured in duplicate in a 96-well plate at 5 × 105 cells 
per well in IMDM containing 5% FCS, and incubated in the absence or 
presence of rat anti-mouse CD3 antibody (1 μg/ml; SouthernBiotech) for 
72 hours. During the last 18 hours, 3H-thymidine (10 μCi/ml; GE Health-
care) was added to the cultures for evaluation of cell proliferation using a 
scintillation counter (PerkinElmer).
Hematology and plasma biochemistry. Whole blood (EDTA) was analyzed 
by a Scil Vet abc hemocounter (Scil). Clinical biochemistry profiling of 
plasma was made on a Vitros DT60II Chemistry System (Ortho Clinical 
Diagnostics, Johnson & Johnson Co.) as described previously (40).
Lipoprotein analysis. Lipoprotein profiles were analyzed using a micro- 
FPLC column (30 × 0.32 cm Superose 6B; GE Healthcare) coupled to a 
system for online separation and subsequent detection of cholesterol (41). 
Plasma cholesterol and triglycerides were measured using enzymatic colo-
Figure 8
Effects of Treg depletion on sortilin-1, LPL, HL, and PLTP. (A) Immunoblot of liver tissue showing sortilin-1 protein in DT- or PBS-treated 
DEREG/Ldlr–/– mice. Full uncut images of sortilin-1 and tubulin immunoblots are shown in Supplemental Figure 7. (B) Scattergram shows indi-
vidual values expressed as a ratio of sortilin-1 protein expression to α–tubulin protein expression. (C) LPL activity in postheparin plasma was 
measured using [3H]-labeled triolein in an emulsion with Intralipid 10% composition as the enzyme substrate; n = 10 (PBS); n = 9 (DT). (D) HL 
activity in postheparin plasma was measured using a gum arabic–stabilized emulsion; n = 10 (PBS); n = 9 (DT). (E) PLTP activity was measured 
using an exogenous lipoprotein-independent phospholipid transfer assay; n = 10 (PBS); n = 10 (DT). All data are from DEREG/Ldlr–/– mice treated 
for 8 weeks with DT or PBS. Mean ± SEM is shown. *P < 0.05; **P < 0.01.
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ribonucleosyltransferase (Hprt) used as the housekeeping gene, and was run 
on an ABI 7900 HT Fast RT-PCR system (all Applied Biosystems). Data were 
analyzed on the basis of the relative expression method with the formula: 
2–ΔΔCT, where ΔΔCT = ΔCT (sample) – ΔCT (calibrator = average CT values of 
all samples), and ΔCT is the CT of the Hprt housekeeping gene subtracted 
from the CT of the target gene (52).
Western blot analysis. Total proteins were isolated from a 25-mg liver sam-
ple using T-PER (Thermo Scientific) and homogenized with glass homog-
enizers. Protein concentration was determined by the Bradford assay and 
adjusted to 1.5 mg/ml. Thirty-microgram samples were diluted with 2× 
Laemmli sample buffer, boiled, separated by electrophoresis using 4%–15% 
Mini-PROTEAN TGX Precast Gels, and transferred to a PVDF membrane 
(all Bio-Rad). Sortilin-1 was detected using a rabbit polyclonal anti–sortilin 
antibody (ab16640; Abcam), followed by peroxidase-labeled goat anti-rabbit 
IgG (Dako), and visualized using an ECL system (GE Healthcare). Rabbit 
anti-tubulin antibody (ab4074, Abcam) was used as a loading control. Quan-
tification was performed using the ImageJ software (NIH) gel analyzer tool.
Statistics. Values are expressed as mean ± SEM unless otherwise indicated. 
Groupwise comparisons (n >2) were performed using a nonparametric Krus-
kal-Wallis test followed by a Mann-Whitney U test as appropriate. Pairwise 
comparisons were performed using a nonparametric Mann-Whitney  test 
unless otherwise indicated. Spearman’s rank correlation test was performed 
to assess correlations. Statistics performed for the arrays are described in that 
section. A P value less than 0.05 was considered significant. All experiments 
reported here were repeated at least twice with similar results.
Study approval. All animal experiments were approved by the Stockholm 
Regional Board for Animal Ethics.
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as described elsewhere (44). Chimeric DEREG/Ldlr–/– mice treated for 8 
weeks with DT or PBS and fed a high-cholesterol diet were injected with 
CMs corresponding to 2 mg triglycerides through the tail vein, and blood 
was collected after 1, 3, 7, and 15 minutes from the retro-orbital vein 
plexus in temporarily isoflurane-anesthetized animals. After the final 
bleeding, the mice were sacrificed and their tissues were collected and 
rinsed in PBS. Blood samples were extracted for esterified lipids as previ-
ously described (44), traced for the radiolabeled moieties, and corrected 
for weight. Tissue samples were homogenized in chloroform/methanol 
(2:1) using tubes with ceramic beads, total lipids were extracted, and the 
tissues were adjusted for weight.
LPL and HL were released into the plasma with heparin injections (50 
U/kg), and postheparin blood was collected from the tail vein after 15 
minutes into heparin-coated tubes. Plasma was collected by ultracentrif-
ugation and stored at –80°C. LPL activity was assessed in a system using 
[3H]-labeled triolein in an emulsion with Intralipid 10% composition as 
the enzyme substrate. Rat serum was added as apoCII donor (45). HL 
was inhibited using antibodies against rat HL (46). Specific HL activity 
was measured using a gum arabic–stabilized emulsion (47). Postheparin 
plasma lipase activity was determined as the mean of triplicate readings. 
Lipase activity is expressed as mU/ml, where 1 mU corresponds to 1 nmol 
of fatty acid released per minute at 25°C (48). Phospholipid transfer activ-
ity of PLTP was measured with a radiometric activity assay as described by 
Jauhiainen et al. (49) using an exogenous, lipoprotein-independent phos-
pholipid transfer assay with labeled phospholipid vesicles as a substrate.
RNA isolation. mRNA was isolated from liver, intestine, heart, white adi-
pose tissue, skeletal muscle, spleen, and lung using the RNeasy kit from 
QIAGEN. Total RNA quality was analyzed by an Agilent 2100 BioAn-
alyzer (Agilent Technologies) and quantified using a Nanodrop 1000 
(Thermo Fisher Scientific).
Gene expression array. mRNA of liver and intestine was submitted to a 
core facility (Affymetrix Core Facility, Novum, Huddinge, Sweden and 
Uppsala Array Platform, Uppsala University, Sweden) for hybridization to 
GeneChip Mouse Gene 1.0 ST Arrays (Affymetrix). The microarray expres-
sion data were preprocessed with R statistical software (50) using the RMA 
method as implemented in the Affymetrix package. Differential expression 
analysis was performed with the moderated t statistic and false discovery 
rate (FDR) multiple test correction methods from the limma package. 
Transcripts with an FDR less than 0.1 and an absolute linear fold change 
greater than 1.5 were considered significantly differentially expressed. 
The raw microarray expression data have been deposited in NCBI’s Gene 
Expression Omnibus (Gene Expression Omnibus accession numbers 
GSE36279 for liver and GSE39351 for intestine; http://www.ncbi.nlm.nih.
gov/geo). The differentially expressed genes were clustered according to 
their annotation using the DAVID Bioinformatics Resource to identify sig-
nificantly enriched functional annotation terms in the categories of gene 
ontology and pathways (51).
Real-time PCR. Superscript-II and random hexamers (both from 
Invitrogen) were used for reverse transcription. Real-time PCR used 
TaqMan Universal Master Mix and premanufactured primers and probes 
(Assay-on-Demand) for genes of interest, with hypoxanthine guanidine 
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